GSK: two-drug HIV regimen as effective as three-drug regimen
(CercleFinance.com) - GSK's ViiV Healthcare said on Monday its 2-drug regimen proved to be as effective as a 3-drug regimen in adults with HIV-1 in two phase III studies.
A pooled analysis of the two studies showed that dolutegravir plus lamivudine demonstrated non-inferiority, with 82% of participants having a viral loads of less than 50 copies per millilitre (c/mL) at week 144, compared with 84% of participants receiving a 3-drug regimen.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
A pooled analysis of the two studies showed that dolutegravir plus lamivudine demonstrated non-inferiority, with 82% of participants having a viral loads of less than 50 copies per millilitre (c/mL) at week 144, compared with 84% of participants receiving a 3-drug regimen.
Copyright (c) 2020 CercleFinance.com. All rights reserved.